WEBVTT 00:00:00.000 --> 00:00:02.100 Welcome back to the Deep Dive. You've handed 00:00:02.100 --> 00:00:04.879 us a blueprint today, a set of sources charting 00:00:04.879 --> 00:00:09.699 the history of a company that is arguably the 00:00:09.699 --> 00:00:13.439 perfect microcosm of modern biotechnology, Biogen 00:00:13.439 --> 00:00:17.039 Inc. It really is. This is a story of incredible, 00:00:17.280 --> 00:00:20.260 I mean, Nobel Prize level scientific ambition 00:00:20.260 --> 00:00:23.800 juxtaposed with operational risk and... Frankly, 00:00:24.059 --> 00:00:26.600 ethical turbulence that few companies can match. 00:00:26.800 --> 00:00:28.239 That's the core tension right there, isn't it? 00:00:28.300 --> 00:00:30.300 The thing we really need to explore. Biogen is 00:00:30.300 --> 00:00:32.820 an American multinational biotech titan, but 00:00:32.820 --> 00:00:35.799 its specialization is intensely focused on one 00:00:35.799 --> 00:00:37.679 of the most challenging areas in all of medicine. 00:00:37.899 --> 00:00:39.979 Neurological diseases. Exactly. Neurological 00:00:39.979 --> 00:00:41.880 diseases. We're talking about MS, Alzheimer's, 00:00:41.899 --> 00:00:44.759 ALS, and then these rare conditions like spinal 00:00:44.759 --> 00:00:47.159 muscular atrophy. These are just devastating, 00:00:47.359 --> 00:00:49.600 chronic, and historically untreatable diseases. 00:00:50.000 --> 00:00:52.840 And that desperation for a cure is the high stakes. 00:00:52.969 --> 00:00:55.990 environment Biogen operates in. Our sources track 00:00:55.990 --> 00:00:58.590 its journey from a 1978 startup biotechnology, 00:00:59.090 --> 00:01:01.250 Geneva, I believe. That's right. All the way 00:01:01.250 --> 00:01:05.290 to an S &P 500 powerhouse. Our mission here is 00:01:05.290 --> 00:01:07.189 to understand the mechanics of that evolution, 00:01:07.450 --> 00:01:09.810 you know, how they achieved market dominance 00:01:09.810 --> 00:01:12.849 in certain areas, and critically, how they handled 00:01:12.849 --> 00:01:15.069 the massive controversies that inevitably come 00:01:15.069 --> 00:01:17.650 with such high -risk science. Especially the 00:01:17.650 --> 00:01:20.790 big one. Oh, yeah. The decade -long saga of their 00:01:20.790 --> 00:01:24.140 abandoned Alzheimer's drug. I do Canemap. But 00:01:24.140 --> 00:01:26.379 before we get there, we have to establish the 00:01:26.379 --> 00:01:30.200 sheer scale and the institutional gravity of 00:01:30.200 --> 00:01:33.120 this player. When you hear the name Biogen, you 00:01:33.120 --> 00:01:35.219 need to think beyond just a typical pharmaceutical 00:01:35.219 --> 00:01:37.719 firm. You need to think institutional stability, 00:01:37.959 --> 00:01:39.859 even with all the internal turbulence we're going 00:01:39.859 --> 00:01:41.879 to talk about. The international roots are fascinating, 00:01:42.079 --> 00:01:45.640 starting as Biotechnology Geneva in 1978. But 00:01:45.640 --> 00:01:48.200 their identity now is so firmly cemented in Cambridge, 00:01:48.319 --> 00:01:50.060 Massachusetts. Right in the heart of it all. 00:01:50.180 --> 00:01:52.519 Yeah, right in the world's most concentrated 00:01:52.519 --> 00:01:55.430 biotech -y. And that geographic centering kind 00:01:55.430 --> 00:01:58.510 of belies its massive global financial reach. 00:01:58.689 --> 00:02:00.989 When we talk scale, we're talking about a company 00:02:00.989 --> 00:02:03.629 that, according to the 2024 financial reports, 00:02:03.750 --> 00:02:07.790 generated annual revenue of U .S. $9 .676 billion. 00:02:08.270 --> 00:02:11.830 Wow. $9 .6 billion. And their total assets are 00:02:11.830 --> 00:02:16.569 reported at U .S. $28 .05 billion. This isn't 00:02:16.569 --> 00:02:18.449 just a successful company. This is a capital 00:02:18.449 --> 00:02:22.129 engine. It employs, what, 7 ,605 people as of 00:02:22.129 --> 00:02:25.250 2024? And it holds a solid spot on the NASDAQ 00:02:25.250 --> 00:02:28.330 100, the S &P 500. It's number 424 on the Fortune 00:02:28.330 --> 00:02:31.289 500 list. So they have the financial muscle to 00:02:31.289 --> 00:02:34.310 take massive gambles, which, as we're about to 00:02:34.310 --> 00:02:37.080 see, they do. Frequently. Okay, let's unpack 00:02:37.080 --> 00:02:39.520 this history because the origin story of Biogen 00:02:39.520 --> 00:02:41.740 is, it's just remarkable. It doesn't start with 00:02:41.740 --> 00:02:43.879 venture capitalists. It starts with pure scientific 00:02:43.879 --> 00:02:45.939 pedigree. That's the key. The founding group 00:02:45.939 --> 00:02:49.439 in 1978 was a biological dream team. It was this 00:02:49.439 --> 00:02:51.699 intentional meeting of five of the era's most 00:02:51.699 --> 00:02:53.900 prominent research biologists. It was a very 00:02:53.900 --> 00:02:56.919 conscious effort to translate pure academic discovery 00:02:56.919 --> 00:02:59.120 into commercial medicine. This was not typical 00:02:59.120 --> 00:03:01.139 startup fair, you know. You had these leading 00:03:01.139 --> 00:03:03.580 lights from European and American institutions. 00:03:03.919 --> 00:03:06.770 So who were they? You had Kenneth Murray, a pioneer 00:03:06.770 --> 00:03:08.729 in gene sequencing from the University of Edinburgh, 00:03:09.030 --> 00:03:11.909 Philip Alan Sharp, a foundational geneticist 00:03:11.909 --> 00:03:14.490 from MIT, Heinz Schaller from the University 00:03:14.490 --> 00:03:16.750 of Heidelberg, and Charles Weissman from the 00:03:16.750 --> 00:03:18.909 University of Zurich. And crucially, the CEO 00:03:18.909 --> 00:03:22.110 at the launch was a co -founder who was also 00:03:22.110 --> 00:03:24.610 a scientific giant himself. That's Walter Gilbert 00:03:24.610 --> 00:03:27.069 from Harvard University. He stepped in as the 00:03:27.069 --> 00:03:30.229 initial CEO, which just cemented that immediate 00:03:30.229 --> 00:03:33.110 high -level scientific oversight. And it was 00:03:33.110 --> 00:03:35.490 Charles Weissman who provided the company's very 00:03:35.490 --> 00:03:38.629 first product. Interferon Alpha. Interferon Alpha, 00:03:38.849 --> 00:03:41.610 a key protein used in the immune response and 00:03:41.610 --> 00:03:44.210 really foundational for early viral treatments. 00:03:44.490 --> 00:03:46.969 This shows that direct link between the academic 00:03:46.969 --> 00:03:49.129 lab bench and the initial commercial pipeline. 00:03:49.430 --> 00:03:51.930 And the company's foundational prestige was validated 00:03:51.930 --> 00:03:55.150 almost immediately. It's not often you hear that 00:03:55.150 --> 00:03:56.990 two of the company's founding scientists went 00:03:56.990 --> 00:03:59.610 on to win Nobel Prizes after the company was 00:03:59.610 --> 00:04:01.610 already up and running. It just speaks volumes 00:04:01.610 --> 00:04:03.870 about the intellectual capital they were built 00:04:03.870 --> 00:04:06.469 on, right? Walter Gilbert was awarded the Nobel 00:04:06.469 --> 00:04:09.650 Prize in Chemistry in 1980, recognized for his 00:04:09.650 --> 00:04:11.969 revolutionary understanding of DNA sequencing. 00:04:12.310 --> 00:04:15.090 Okay. Then, just over a decade later, Philip 00:04:15.090 --> 00:04:18.329 Alan Sharpe shared the 1993 Nobel Prize in Physiology 00:04:18.329 --> 00:04:20.470 or Medicine for his groundbreaking discovery 00:04:20.470 --> 00:04:23.290 of split genes. Which fundamentally changed how 00:04:23.290 --> 00:04:25.350 we understand genetic information. Completely. 00:04:25.370 --> 00:04:28.449 That kind of legacy in foundational genetic and 00:04:28.449 --> 00:04:31.850 molecular science gives Biogen this unique... 00:04:32.279 --> 00:04:35.500 almost untouchable scientific credibility. It 00:04:35.500 --> 00:04:37.360 really underpins their ability to seek these 00:04:37.360 --> 00:04:40.120 highly ambitious, high -risk targets today. So 00:04:40.120 --> 00:04:42.420 that deep scientific foundation really set the 00:04:42.420 --> 00:04:45.240 stage for their first major transformation, the 00:04:45.240 --> 00:04:47.939 2003 merger. The transition to Biogen IDEC was 00:04:47.939 --> 00:04:51.339 absolutely pivotal. They merged with IDC Pharmaceuticals, 00:04:51.339 --> 00:04:54.040 a San Diego -based company founded in 1985 by 00:04:54.040 --> 00:04:56.379 a different breed of expert. Okay. We're talking... 00:04:56.800 --> 00:04:59.079 Physicians, immunologists, cancer researchers, 00:04:59.279 --> 00:05:02.060 primarily from UC San Diego and Stanford. So 00:05:02.060 --> 00:05:03.819 this merger wasn't just about combining balance 00:05:03.819 --> 00:05:05.259 sheets. It was about combining technological 00:05:05.259 --> 00:05:08.660 platforms. And the resulting entity instantly 00:05:08.660 --> 00:05:11.560 leaped up the global biotech rankings. Instantly. 00:05:11.959 --> 00:05:14.639 Biogen Idec immediately became the third largest 00:05:14.639 --> 00:05:17.220 biotechnology company in the world by market 00:05:17.220 --> 00:05:19.920 cap at the time. And what did IDIC bring to the 00:05:19.920 --> 00:05:22.199 table? They brought more than just a cancer pipeline. 00:05:22.399 --> 00:05:25.850 They brought R2 -Exan or Rituximab. This was 00:05:25.850 --> 00:05:29.129 a revolutionary piece of science. The very first 00:05:29.129 --> 00:05:31.990 monoclonal antibody developed and approved for 00:05:31.990 --> 00:05:34.850 cancer treatment. We need to pause on Ritugazian 00:05:34.850 --> 00:05:37.490 for a moment because simply saying it was the 00:05:37.490 --> 00:05:39.790 first AMI for cancer undersells its significance, 00:05:40.029 --> 00:05:41.970 doesn't it? Why was this such a foundational 00:05:41.970 --> 00:05:45.009 shift? Well, because before monoclonal antibodies, 00:05:45.290 --> 00:05:47.709 the primary weapon against cancer was, you know, 00:05:47.769 --> 00:05:50.089 non -selective chemotherapy. Right, which just 00:05:50.089 --> 00:05:52.230 kills everything. It kills rapidly dividing cells 00:05:52.230 --> 00:05:54.370 indiscriminately, leading to those awful side 00:05:54.370 --> 00:05:57.110 effects. R -E -T -U -X -N represented the beginning 00:05:57.110 --> 00:05:59.730 of targeted therapy. As a monoclonal antibody, 00:06:00.050 --> 00:06:02.649 it was engineered to recognize and bind specifically 00:06:02.649 --> 00:06:06.209 to a protein CD20 found on the surface of B cells. 00:06:06.430 --> 00:06:09.089 The cancer cells. The ones that are often overexpressed 00:06:09.089 --> 00:06:11.829 in certain lymphomas. This allowed it to flag 00:06:11.829 --> 00:06:14.149 the cancerous cells for destruction by the immune 00:06:14.149 --> 00:06:17.709 system while sparing most healthy tissue. And 00:06:17.709 --> 00:06:20.930 that technology, targeted protein therapy, became 00:06:20.930 --> 00:06:23.709 central to Biogen's future work. Including their 00:06:23.709 --> 00:06:26.269 later Alzheimer's strategy. Exactly. So the IDEC 00:06:26.269 --> 00:06:28.790 merger not only expanded their market, but it 00:06:28.790 --> 00:06:31.110 also diversified their technological expertise, 00:06:31.589 --> 00:06:34.350 preparing them for that next wave of biological 00:06:34.350 --> 00:06:36.689 engineering. Yet they eventually shifted back 00:06:36.689 --> 00:06:39.670 to just Biogen in 2015. Right. They dropped the 00:06:39.670 --> 00:06:42.129 IDEC. And that name change reflected a renewed 00:06:42.129 --> 00:06:45.269 and intensive focus. Following the merger, Biogen 00:06:45.269 --> 00:06:47.899 IDEC had this cancer program. But the leadership 00:06:47.899 --> 00:06:50.620 decided that the highest value, least met medical 00:06:50.620 --> 00:06:54.120 need was in neurology. So they streamlined. Simplifying 00:06:54.120 --> 00:06:56.459 the name back to Biogen signaled a deliberate 00:06:56.459 --> 00:06:59.339 corporate strategy to shed non -core assets and 00:06:59.339 --> 00:07:02.600 to double down on complex neurological disorders, 00:07:02.839 --> 00:07:05.620 which would require massive sustained R &D investment. 00:07:05.959 --> 00:07:07.819 And that investment was quickly backed up by 00:07:07.819 --> 00:07:10.240 strategic acquisitions that really locked in 00:07:10.240 --> 00:07:13.240 their future therapeutic focus. Let's review 00:07:13.240 --> 00:07:15.420 those early moves that shaped their pipeline. 00:07:15.870 --> 00:07:18.290 The post -merger consolidation phase was highly 00:07:18.290 --> 00:07:22.250 focused. In 2006, they acquired Conforma Therapeutics 00:07:22.250 --> 00:07:26.310 for $250 million, a cancer specialist. Which 00:07:26.310 --> 00:07:28.649 seems a bit contradictory to the neurology focus. 00:07:29.089 --> 00:07:32.250 It does, but it often involves overlapping molecular 00:07:32.250 --> 00:07:34.750 biology principles. More importantly, though, 00:07:34.850 --> 00:07:37.730 in the same year, they acquired Fumafarm AG. 00:07:38.069 --> 00:07:40.110 And that Fumafarm acquisition was the critical 00:07:40.110 --> 00:07:42.629 foundation for their future MS dominance, wasn't 00:07:42.629 --> 00:08:08.079 it? Absolutely, 100%. Okay. So that was a smart 00:08:08.079 --> 00:08:15.420 move. What? What other moves were they making 00:08:15.420 --> 00:08:17.199 during this period to shore up their technical 00:08:17.199 --> 00:08:20.379 capabilities? In 2007, they acquired Centonix 00:08:20.379 --> 00:08:24.500 Pharmaceuticals for up to $120 million. Syntenix 00:08:24.500 --> 00:08:27.240 was focused on hemophilia B, but the true strategic 00:08:27.240 --> 00:08:30.540 value was the delivery technology. They acquired 00:08:30.540 --> 00:08:32.940 the technology for developing inhalable treatments, 00:08:33.159 --> 00:08:35.299 which is a crucial capability for a company that 00:08:35.299 --> 00:08:38.059 often deals with large molecule drugs that are, 00:08:38.179 --> 00:08:41.059 you know, difficult to administer. So these early 00:08:41.059 --> 00:08:43.759 strategic moves weren't just about drugs. No, 00:08:43.820 --> 00:08:45.980 not at all. They were about securing delivery 00:08:45.980 --> 00:08:48.539 systems and pipelines that allowed them to tackle 00:08:48.539 --> 00:08:52.440 chronic, high -cost, and complex diseases efficiently. 00:08:53.360 --> 00:08:55.279 Transition from the foundation to the financial 00:08:55.279 --> 00:08:58.879 engine. Biogen's portfolio is concentrated, and 00:08:58.879 --> 00:09:01.940 it's deeply rooted in multiple sclerosis, a condition 00:09:01.940 --> 00:09:04.279 where the immune system attacks the central nervous 00:09:04.279 --> 00:09:06.309 system. And that concentration is significant. 00:09:06.649 --> 00:09:10.389 MS drugs alone constituted a dominant 45 % of 00:09:10.389 --> 00:09:14.190 Biogen's 2024 total revenues. 45%. And they intentionally 00:09:14.190 --> 00:09:17.269 offer a full spectrum of treatments. So for patients 00:09:17.269 --> 00:09:19.909 who prefer oral administration, there's Texfidera, 00:09:19.929 --> 00:09:22.289 which is dimethylfumerate, and the less frequent 00:09:22.289 --> 00:09:25.149 dosing option, Vumerity. And they also maintain 00:09:25.149 --> 00:09:28.129 a strong presence in the older injectable market. 00:09:28.309 --> 00:09:31.090 Correct. The older workhorses like Avonax and 00:09:31.090 --> 00:09:33.889 Plegrity still generate substantial revenue and 00:09:33.889 --> 00:09:36.210 provide options for patients who may not tolerate 00:09:36.210 --> 00:09:38.570 the oral treatments or who have been successfully 00:09:38.570 --> 00:09:41.269 managed on injectables for years. A robust portfolio. 00:09:41.570 --> 00:09:44.110 It ensures Biogen maintains market share across 00:09:44.110 --> 00:09:47.129 the entire MS patient population. But within 00:09:47.129 --> 00:09:50.870 that highly successful portfolio is Tisabri or 00:09:50.870 --> 00:09:53.809 Nitalizumab, a drug that forces the company to 00:09:53.809 --> 00:09:56.370 walk a very fine line between clinical benefit 00:09:56.370 --> 00:09:59.590 and a catastrophic side effect. Tysabri is a 00:09:59.590 --> 00:10:02.330 classic example of high efficacy, high risk medicine. 00:10:02.590 --> 00:10:05.529 It's common in neurology. It's a monoclonal antibody 00:10:05.529 --> 00:10:08.210 that is highly effective at slowing MS progression, 00:10:08.570 --> 00:10:11.690 but it carries a serious, potentially fatal risk. 00:10:11.990 --> 00:10:15.100 Progressive multifocal leukoencephalopathy. Or 00:10:15.100 --> 00:10:18.080 PML. PML, exactly. And the risks became very 00:10:18.080 --> 00:10:20.639 real in the market. What happened? In 2008, new 00:10:20.639 --> 00:10:23.220 cases of PML, which is a severe, debilitating 00:10:23.220 --> 00:10:25.440 viral infection of the brain, surfaced in Europe 00:10:25.440 --> 00:10:28.659 among Tysabri users. This triggered intense international 00:10:28.659 --> 00:10:31.500 regulatory concern and public alarm. I can imagine. 00:10:31.759 --> 00:10:34.720 But the data showed that Tysabri, for some patients, 00:10:34.980 --> 00:10:37.659 provided far superior clinical benefit compared 00:10:37.659 --> 00:10:40.620 to other options. So the challenge for Biogen 00:10:40.620 --> 00:10:44.120 became... How do you manage a drug that is both 00:10:44.120 --> 00:10:46.679 life -changing and potentially life -threatening? 00:10:46.840 --> 00:10:49.659 And they answered by buying Complete Control. 00:10:49.919 --> 00:10:52.320 They made an incredible strategic and financial 00:10:52.320 --> 00:10:56.039 commitment. In 2013, Biogen decided to eliminate 00:10:56.039 --> 00:10:58.340 the joint ownership and bought the full rights 00:10:58.340 --> 00:11:01.179 to Tysabri from their partner, Elon. For how 00:11:01.179 --> 00:11:06.370 much? For a whopping $3 .25 billion. Wow. And 00:11:06.370 --> 00:11:08.909 that price tag, knowing the inherent liability 00:11:08.909 --> 00:11:11.529 and the ongoing need for strict risk management 00:11:11.529 --> 00:11:14.230 programs like regular screening, tells you everything 00:11:14.230 --> 00:11:16.470 you need to know about the drug's clinical superiority 00:11:16.470 --> 00:11:18.789 and its profit potential. They were willing to 00:11:18.789 --> 00:11:20.870 shoulder the massive safety liability because 00:11:20.870 --> 00:11:22.769 the drug was just that effective for a subset 00:11:22.769 --> 00:11:25.149 of patients. It was a calculated risk that has, 00:11:25.269 --> 00:11:27.149 I mean, it's paid off financially for them. And 00:11:27.149 --> 00:11:29.090 to complete their MS picture, they also have 00:11:29.090 --> 00:11:32.110 Vampyra in the EU, which focuses purely on mobility. 00:11:32.559 --> 00:11:35.879 Right. Vampyra addresses a very specific quality 00:11:35.879 --> 00:11:38.759 of life limiting symptom for EU MS patients, 00:11:39.019 --> 00:11:42.460 walking ability. And its regulatory path is really 00:11:42.460 --> 00:11:44.820 insightful. It was initially granted conditional 00:11:44.820 --> 00:11:47.720 marketing approval in 2011. What does conditional 00:11:47.720 --> 00:11:50.419 mean in this case? It's a high stakes deal. It 00:11:50.419 --> 00:11:52.679 signals regulators believe the drug meets an 00:11:52.679 --> 00:11:55.360 urgent need, but requires the company to provide 00:11:55.360 --> 00:11:58.480 additional, usually long term safety and benefit 00:11:58.480 --> 00:12:00.779 data after it's on the market. And they're good. 00:12:00.899 --> 00:12:03.169 They met that burden. and they converted it to 00:12:03.169 --> 00:12:06.149 standard marketing approval in 2017. This just 00:12:06.149 --> 00:12:08.570 exemplifies the incremental, persistent development 00:12:08.570 --> 00:12:11.169 required even for symptomatic treatments. Okay, 00:12:11.230 --> 00:12:13.629 so moving from the steady, massive revenue stream 00:12:13.629 --> 00:12:16.809 of MS, we shift to the truly rare disease breakthroughs, 00:12:16.809 --> 00:12:18.870 where the risk profile is different, but the 00:12:18.870 --> 00:12:21.370 clinical impact is arguably even more profound. 00:12:21.649 --> 00:12:23.470 Definitely. We're talking about spinal muscular 00:12:23.470 --> 00:12:27.450 atrophy, or SMA, and the drug Spinraza. Spinraza, 00:12:27.570 --> 00:12:30.669 or Nusinerson, is a landmark drug for Biogen 00:12:30.669 --> 00:12:32.679 and... for patients. It accounted for a highly 00:12:32.679 --> 00:12:36.600 specialized 16 .2 % of their 2024 revenues. And 00:12:36.600 --> 00:12:38.820 its approval in the U .S. in 2016 marked it as 00:12:38.820 --> 00:12:41.240 the first ever treatment for SMA. The first ever. 00:12:41.460 --> 00:12:44.059 It's a devastating genetic disorder that destroys 00:12:44.059 --> 00:12:46.519 motor nerve cells, leading to muscle wasting, 00:12:46.740 --> 00:12:50.179 mobility loss, and often early death. To understand 00:12:50.179 --> 00:12:52.200 the impact, we need to understand the mechanism. 00:12:52.500 --> 00:12:55.700 How does Spinraza actually work to change the 00:12:55.700 --> 00:12:58.399 prognosis for these patients? So it works by 00:12:58.399 --> 00:13:01.279 addressing the underlying genetic defect. SMA 00:13:01.279 --> 00:13:04.580 is caused by a mutation in the SMN1 gene. Now, 00:13:04.659 --> 00:13:08.080 humans have a backup gene, SMN2, which can produce 00:13:08.080 --> 00:13:10.320 a small amount of the necessary protein, but 00:13:10.320 --> 00:13:12.659 often not enough to prevent the disease from 00:13:12.659 --> 00:13:15.440 progressing. And Spinraza boosts that backup 00:13:15.440 --> 00:13:18.590 gene. Exactly. Spinraza is what's called an antisense 00:13:18.590 --> 00:13:21.289 oligonucleotide. Essentially, it's a short strand 00:13:21.289 --> 00:13:23.850 of synthetic DNA designed to bind to a specific 00:13:23.850 --> 00:13:26.830 sequence of that SMN2 gene, ensuring that the 00:13:26.830 --> 00:13:29.190 gene produces more full -length functional protein. 00:13:29.429 --> 00:13:31.429 It doesn't cure the defect. No, it doesn't cure 00:13:31.429 --> 00:13:33.470 it, but by boosting the protein, it significantly 00:13:33.470 --> 00:13:36.289 mitigates the severity of the disease. This sounds 00:13:36.289 --> 00:13:38.690 like revolutionary precision medicine, but it 00:13:38.690 --> 00:13:40.769 comes with a price tag that has made Spinraza 00:13:40.769 --> 00:13:43.230 a global flashpoint for drug pricing ethics. 00:13:43.529 --> 00:13:46.049 It absolutely ignited one of the most intense 00:13:46.120 --> 00:13:48.440 hence ethical pricing debates in recent memory. 00:13:48.700 --> 00:13:52.879 The price point was, well. astronomical, $750 00:13:52.879 --> 00:13:57.340 ,000 for the first year of loading doses. $750 00:13:57.340 --> 00:14:01.860 ,000. And then $375 ,000 every year thereafter, 00:14:02.120 --> 00:14:03.700 potentially for the rest of the patient's life. 00:14:03.879 --> 00:14:05.500 That's unbelievable. On one hand, you have the 00:14:05.500 --> 00:14:07.899 drug development costs, which was immense. The 00:14:07.899 --> 00:14:10.539 target population is small. And the drug provides 00:14:10.539 --> 00:14:13.500 demonstrable quality of life improvements. I 00:14:13.500 --> 00:14:15.820 mean, in infants, it can be the difference between 00:14:15.820 --> 00:14:18.080 life and respiratory failure. But on the other 00:14:18.080 --> 00:14:21.759 hand. The idea of a lifelong, nearly million 00:14:21.759 --> 00:14:24.840 -dollar annual commitment forces desperate families 00:14:24.840 --> 00:14:26.860 and health care systems into these impossible 00:14:26.860 --> 00:14:30.240 choices. Precisely. It brings into sharp relief 00:14:30.240 --> 00:14:32.860 that tension between market economics and urgent 00:14:32.860 --> 00:14:35.799 medical necessity. Biogen argued the price was 00:14:35.799 --> 00:14:38.179 necessary to recoup the investment. Of course. 00:14:38.340 --> 00:14:40.639 However, for health systems and families, it 00:14:40.639 --> 00:14:43.039 represented a monumental financial burden that 00:14:43.039 --> 00:14:45.460 only served to highlight the vast profit margins 00:14:45.460 --> 00:14:48.919 inherent in orphan drug designation. It's a classic 00:14:48.919 --> 00:14:51.419 example of Biogen translating scientific success 00:14:51.419 --> 00:14:54.960 directly into market leverage. And they're clearly 00:14:54.960 --> 00:14:58.779 committed to this rare niche strategy. We also 00:14:58.779 --> 00:15:02.340 see Omoviloxalone, or SkyClarys, for Friedreich's 00:15:02.340 --> 00:15:06.679 Cetaxia, making up 4 .0 % of 2024 revenues. That 00:15:06.679 --> 00:15:08.919 acquisition and launch just reinforces their 00:15:08.919 --> 00:15:11.720 strategy. Friedreich's ataxia is another progressive 00:15:11.720 --> 00:15:14.600 neurological disease. SkyClaris, approved in 00:15:14.600 --> 00:15:17.379 2023, targets a rare high -impact condition, 00:15:17.639 --> 00:15:20.179 proving that Biogen is doubling down on areas 00:15:20.179 --> 00:15:22.419 where they can command high prices due to unmet 00:15:22.419 --> 00:15:24.600 need and limited competition. We should also 00:15:24.600 --> 00:15:28.580 briefly note Tofresin, or Colsodi for ALS, another 00:15:28.580 --> 00:15:31.039 devastating condition with a huge unmet need 00:15:31.039 --> 00:15:33.519 and the ongoing collaborations they rely on. 00:15:33.720 --> 00:15:35.960 Their revenue diversification includes significant 00:15:35.960 --> 00:15:38.919 collaboration revenue, about 18 .1 % of their 00:15:38.919 --> 00:15:41.340 total, primarily through Genentech. And then 00:15:41.340 --> 00:15:43.700 there's a smaller but growing biosimilar segment 00:15:43.700 --> 00:15:46.059 at 8 .2%. So the business model is structured 00:15:46.059 --> 00:15:48.220 to use those stable high -margin profits. From 00:15:48.220 --> 00:15:51.200 MS and rare diseases, yes. To fund the next generation 00:15:51.200 --> 00:15:53.960 of riskier, cutting -edge R &D, like their pursuit 00:15:53.960 --> 00:15:55.799 of Alzheimer's treatments. Before we get to the 00:15:55.799 --> 00:15:58.159 main event, the Aduholm saga, we have to analyze 00:15:58.159 --> 00:16:00.779 a very shrewd financial move, spinning off their 00:16:00.779 --> 00:16:04.000 hemophilia division. This move in 2017 really 00:16:04.000 --> 00:16:07.539 defined their focus. Biogen spun off its hemophilia 00:16:07.539 --> 00:16:10.220 business, which included the drugs Alprolix and 00:16:10.220 --> 00:16:13.740 Aloctate, into a new separate publicly traded 00:16:13.740 --> 00:16:16.720 company called BioVerative. A powerful corporate 00:16:16.720 --> 00:16:19.600 signal. A very powerful signal. It showed that 00:16:19.600 --> 00:16:21.740 while hemophilia was a profitable, successful 00:16:21.740 --> 00:16:25.899 franchise, it did not fit the extreme high risk 00:16:25.899 --> 00:16:28.700 neurological specialization Biogen had committed 00:16:28.700 --> 00:16:31.299 to. And the market immediately validated that 00:16:31.299 --> 00:16:33.399 strategic spinoff. Almost immediately. And it 00:16:33.399 --> 00:16:35.940 was highly profitable. BioVeritiv was acquired 00:16:35.940 --> 00:16:38.580 by the French pharmaceutical giant Sanofi in 00:16:38.580 --> 00:16:43.940 2018 for a staggering $11 .6 billion. $11 .6 00:16:43.940 --> 00:16:46.700 billion. So Biogen successfully unlocked massive 00:16:46.700 --> 00:16:49.139 strategic value from assets that were considered 00:16:49.139 --> 00:16:51.759 non -core to their main mission, demonstrating 00:16:51.759 --> 00:16:53.860 expert management of their corporate portfolio 00:16:53.860 --> 00:16:56.200 and, you know, freeing up capital for their next 00:16:56.200 --> 00:16:58.840 massive undertaking. If Biogen's entire history 00:16:58.840 --> 00:17:01.840 is a calculation of risk versus reward, the story 00:17:01.840 --> 00:17:04.720 of adikonomab, branded as Aduhelm, is the moment 00:17:04.720 --> 00:17:07.180 they rolled the dice on the biggest, most emotionally 00:17:07.180 --> 00:17:10.279 charged disease target in the world, Alzheimer's. 00:17:10.339 --> 00:17:13.240 This is it. This is the core narrative of modern 00:17:13.240 --> 00:17:16.299 high -stakes biotech. This story just encapsulates 00:17:16.299 --> 00:17:18.700 the tension between scientific hope, regulatory 00:17:18.700 --> 00:17:21.380 pressure, and the desperate urgency of patients. 00:17:22.619 --> 00:17:25.440 Aducanumab was licensed early, way back in 2007, 00:17:25.559 --> 00:17:28.240 from NeurImmune, a scientific spinoff from the 00:17:28.240 --> 00:17:30.609 University of Zurich. And the drug was based 00:17:30.609 --> 00:17:33.210 on the amyloid hypothesis. Right. The premise 00:17:33.210 --> 00:17:35.670 that removing amyloid beta plaques from the brain 00:17:35.670 --> 00:17:38.789 would stop or slow cognitive decline. And early 00:17:38.789 --> 00:17:40.769 results suggest that that premise might actually 00:17:40.769 --> 00:17:43.769 work. They provided enormous scientific justification 00:17:43.769 --> 00:17:47.410 for moving forward. By late 2014 and early 2015, 00:17:47.750 --> 00:17:50.809 initial studies showed significant promise. Not 00:17:50.809 --> 00:17:52.869 only did the drug achieve the biological goal 00:17:52.869 --> 00:17:55.309 of reducing amyloid beta plaques in the brain. 00:17:55.470 --> 00:17:58.109 Which is huge in itself. Huge. But in early stage 00:17:58.109 --> 00:18:00.299 patients, there were also reported, albeit small, 00:18:00.500 --> 00:18:03.240 improvements in cognition. This was revolutionary 00:18:03.240 --> 00:18:05.799 because no drug had ever definitively achieved 00:18:05.799 --> 00:18:08.319 both biological clearance and cognitive benefit 00:18:08.319 --> 00:18:10.799 at the same time. This success propelled them 00:18:10.799 --> 00:18:13.079 immediately into the most expensive and complex 00:18:13.079 --> 00:18:15.640 stage of drug testing. It demanded a massive 00:18:15.640 --> 00:18:19.740 commitment. In July 2015, Iogen initiated two 00:18:19.740 --> 00:18:23.099 monumental late -stage Phase III studies, Engage 00:18:23.099 --> 00:18:25.940 and Emerge. They were designed to definitively 00:18:25.940 --> 00:18:28.910 assess the drug's effectiveness and safety. And 00:18:28.910 --> 00:18:31.150 then the mechanism was confirmed in 2016. Right. 00:18:31.230 --> 00:18:33.369 A high -profile report in the journal Nature 00:18:33.369 --> 00:18:35.769 validated the decrease of amyloid beta in the 00:18:35.769 --> 00:18:38.490 brains of patients receiving the treatment. The 00:18:38.490 --> 00:18:41.470 hope was sky high. Yet, despite the massive investment 00:18:41.470 --> 00:18:44.069 and early hope, the journey hit a sudden dramatic 00:18:44.069 --> 00:18:48.960 wall in 2019. March 20 West, 2019. That date 00:18:48.960 --> 00:18:51.420 is a perfect demonstration of the brutality of 00:18:51.420 --> 00:18:54.380 clinical trials. Biogen stunned the investment 00:18:54.380 --> 00:18:56.220 world by announcing that the phase three trials 00:18:56.220 --> 00:18:59.339 were being halted. Why? An independent data monitoring 00:18:59.339 --> 00:19:01.859 committee performed an interim analysis and concluded 00:19:01.859 --> 00:19:04.059 the trials were unlikely to meet their primary 00:19:04.059 --> 00:19:07.220 endpoint, a finding of futility. So the drug, 00:19:07.240 --> 00:19:09.519 based on the statistical models, simply wasn't 00:19:09.519 --> 00:19:11.740 working. That was the conclusion. Biogen shares 00:19:11.740 --> 00:19:14.140 dropped sharply, the market priced the drug as 00:19:14.140 --> 00:19:16.579 a total failure, and the decade -long dream seemed 00:19:16.579 --> 00:19:19.720 dead. But the story took an unprecedented stunning 00:19:19.720 --> 00:19:22.690 reversal just months later. It was an extraordinary 00:19:22.690 --> 00:19:26.069 scientific and regulatory maneuver. In October 00:19:26.069 --> 00:19:29.609 2019, Biogen performed a complete about -face. 00:19:29.890 --> 00:19:32.509 They announced plans to revive the drug and pursue 00:19:32.509 --> 00:19:35.109 FDA approval. And their justification. It was 00:19:35.109 --> 00:19:38.190 complex. They conducted a new analysis of a much 00:19:38.190 --> 00:19:40.750 larger patient pool that included more complete 00:19:40.750 --> 00:19:43.809 data. And they suggested that patients who received 00:19:43.809 --> 00:19:46.950 higher doses for longer durations in one of the 00:19:46.950 --> 00:19:49.950 trials, the eMERGE trial, did show promising 00:19:49.950 --> 00:19:53.029 results in slowing cognitive decline. So they 00:19:53.029 --> 00:19:55.630 essentially found a positive signal hidden within 00:19:55.630 --> 00:19:58.119 the massive data set. Of the previously declared 00:19:58.119 --> 00:20:00.160 failure. That's what they claim. But knowing 00:20:00.160 --> 00:20:02.640 that the independent panel had declared futility, 00:20:02.839 --> 00:20:06.119 was this reversal driven purely by science? Or 00:20:06.119 --> 00:20:08.380 was there intense market pressure to deliver 00:20:08.380 --> 00:20:10.759 something on their massive investment? It's likely 00:20:10.759 --> 00:20:13.200 a blend of both, right? The high stakes nature 00:20:13.200 --> 00:20:15.539 of the disease, the vastness of the untapped 00:20:15.539 --> 00:20:18.019 market, and the sheer cost of the phase three 00:20:18.019 --> 00:20:20.420 program meant the pressure to find any positive 00:20:20.420 --> 00:20:23.440 signal was immense. So the scientific basis was 00:20:23.440 --> 00:20:25.559 controversial from the start. Highly controversial. 00:20:26.319 --> 00:20:29.339 It wasn't based on a new trial, but a retrospective 00:20:29.339 --> 00:20:32.500 reanalysis of a failed trial. But Biogen had 00:20:32.500 --> 00:20:34.940 enough confidence in that small positive signal 00:20:34.940 --> 00:20:38.119 to commit fully to commercial preparation. And 00:20:38.119 --> 00:20:40.839 the commercial world reacted instantly, anticipating 00:20:40.839 --> 00:20:43.660 the drug's arrival. Absolutely. Biogen doubled 00:20:43.660 --> 00:20:46.420 down on manufacturing. They accelerated construction 00:20:46.420 --> 00:20:48.859 on their state -of -the -art facility in Solothurn, 00:20:48.900 --> 00:20:51.619 Switzerland, alongside their North Carolina facility. 00:20:51.900 --> 00:20:53.940 All designed to churn out this monoclonal antibody 00:20:53.940 --> 00:20:56.240 at scale. And the investment community clearly 00:20:56.240 --> 00:20:58.809 bought into the revived hope. Warren Buffett's 00:20:58.809 --> 00:21:02.250 Berkshire Hathaway bought over $192 million worth 00:21:02.250 --> 00:21:05.349 of shares, a very strong signal of major investor 00:21:05.349 --> 00:21:08.089 confidence. This set the stage for the final 00:21:08.089 --> 00:21:10.549 regulatory showdown, which became one of the 00:21:10.549 --> 00:21:12.990 most controversial FDA decisions in decades. 00:21:13.349 --> 00:21:15.910 Biogen and their collaborator Izai submitted 00:21:15.910 --> 00:21:18.869 the biologics license application, or BLA, in 00:21:18.869 --> 00:21:21.769 July 2020, and they requested the accelerated 00:21:21.769 --> 00:21:24.529 review pathway. But the internal conflict at 00:21:24.529 --> 00:21:27.380 the FDA became public. It did. In November 2020, 00:21:27.660 --> 00:21:30.119 the FDA advisory panel, these are the outside 00:21:30.119 --> 00:21:32.200 experts tasked with providing impartial review, 00:21:32.359 --> 00:21:35.480 voted overwhelmingly against approval. They expressed 00:21:35.480 --> 00:21:38.119 serious, deep -seated doubts about the clinical 00:21:38.119 --> 00:21:41.019 efficacy data from the reanalysis. Yet, despite 00:21:41.019 --> 00:21:45.380 that strong advisory rejection, the FDA overruled 00:21:45.380 --> 00:21:49.190 its own panel. On June 7th, 2021, the FDA granted 00:21:49.190 --> 00:21:52.109 accelerated approval to Aducanumab under the 00:21:52.109 --> 00:21:55.329 brand name Aduhelm. And this decision was instantly 00:21:55.329 --> 00:21:57.589 polarizing because the FDA chose to disregard 00:21:57.589 --> 00:22:00.009 the unanimous skepticism of its expert committee. 00:22:00.210 --> 00:22:03.150 What was the specific justification for overriding 00:22:03.150 --> 00:22:05.329 the panel and invoking that accelerated approval 00:22:05.329 --> 00:22:07.960 pathway? This is where regulatory language becomes 00:22:07.960 --> 00:22:10.359 so critical. The FDA invoked the accelerated 00:22:10.359 --> 00:22:12.559 approval pathway, which is typically reserved 00:22:12.559 --> 00:22:14.700 for drugs treating serious conditions where there's 00:22:14.700 --> 00:22:17.440 no existing therapy. The key justification was 00:22:17.440 --> 00:22:19.900 that Aduhelm had been proven to reduce amyloid 00:22:19.900 --> 00:22:22.950 beta plaques in the brain. The FDA deemed this 00:22:22.950 --> 00:22:25.509 plaque reduction a surrogate endpoint, meaning 00:22:25.509 --> 00:22:27.650 it was likely to predict a clinical benefit to 00:22:27.650 --> 00:22:29.569 the patient. So they traded certainty for speed. 00:22:29.869 --> 00:22:32.910 Exactly. They recognized the urgency for Alzheimer's 00:22:32.910 --> 00:22:35.470 patients but lacked definitive proof of long 00:22:35.470 --> 00:22:38.609 -term cognitive improvement. And crucially, the 00:22:38.609 --> 00:22:41.789 approval came with a mandate. Biogen had to conduct 00:22:41.789 --> 00:22:44.490 a required post -approval phase 4 clinical trial 00:22:44.490 --> 00:22:46.849 to definitively verify the clinical benefit. 00:22:47.029 --> 00:22:49.710 If that trial failed, the drug could be taken 00:22:49.710 --> 00:22:52.059 off the market. It was a calculated regulatory 00:22:52.059 --> 00:22:55.440 gamble based on desperation. But the commercial 00:22:55.440 --> 00:22:58.779 failure began almost immediately. Starting with 00:22:58.779 --> 00:23:00.900 the staggering cost. The initial pricing decision 00:23:00.900 --> 00:23:03.480 was commercially devastating. Biogen set the 00:23:03.480 --> 00:23:06.519 price at 56 ,000 U .S. dollars per patient per 00:23:06.519 --> 00:23:09.859 year. 56 ,000. And this high cost coupled with 00:23:09.859 --> 00:23:12.599 the profound controversy and the clinical ambiguity, 00:23:12.859 --> 00:23:15.420 it created a perfect commercial choke point. 00:23:15.559 --> 00:23:18.039 Why did major insurers in the government balk 00:23:18.039 --> 00:23:20.539 at covering it? Payers operate on cost effectiveness 00:23:20.539 --> 00:23:23.640 data. Major insurers openly refused coverage, 00:23:23.839 --> 00:23:25.460 stating they would wait for definitive proof, 00:23:25.680 --> 00:23:27.839 the outcome of that mandatory phase four trial, 00:23:27.940 --> 00:23:30.180 that the drug actually improved patient outcomes, 00:23:30.299 --> 00:23:32.299 not just reduced plaques. And the U .S. government? 00:23:32.440 --> 00:23:34.839 The U .S. government, through Medicare, did not 00:23:34.839 --> 00:23:37.059 subsidize the drug outside of approved clinical 00:23:37.059 --> 00:23:39.839 trials, which significantly limited immediate 00:23:39.839 --> 00:23:43.559 market access. With no guaranteed payment, hospitals 00:23:43.559 --> 00:23:46.400 were reluctant to stock it, and doctors faced 00:23:46.400 --> 00:23:49.019 immense administrative hurdles. So the combination 00:23:49.019 --> 00:23:51.740 of clinical doubt and extreme cost effectively 00:23:51.740 --> 00:23:55.660 choked the drug's adoption. Completely. So after 00:23:55.660 --> 00:23:58.630 a decade of research... Billions invested and 00:23:58.630 --> 00:24:01.670 the highest possible regulatory drama, the Aduhelm 00:24:01.670 --> 00:24:04.410 Odyssey reached its inevitable conclusion. The 00:24:04.410 --> 00:24:06.869 end of the road. It was. The financial realities 00:24:06.869 --> 00:24:09.650 became insurmountable. Facing negligible commercial 00:24:09.650 --> 00:24:12.049 uptake and the ongoing requirement for expensive 00:24:12.049 --> 00:24:14.809 follow -up trials, Biogen officially abandoned 00:24:14.809 --> 00:24:17.690 the drug in January 2024, citing financial reasons 00:24:17.690 --> 00:24:20.210 for the decision. What a story. The saga concluded 00:24:20.210 --> 00:24:23.049 as a monumental financial loss, a cautionary 00:24:23.049 --> 00:24:25.329 tale about accelerated approval, and a perfect 00:24:25.329 --> 00:24:27.970 example of the high st - all -or -nothing nature 00:24:27.970 --> 00:24:30.970 of biotech. So Biogen emerged from the out -of 00:24:30.970 --> 00:24:33.750 -home failure damaged but financially solvent. 00:24:33.990 --> 00:24:36.630 The job now was to refocus their massive financial 00:24:36.630 --> 00:24:39.089 muscle. Let's look at how they've been strategically 00:24:39.089 --> 00:24:41.569 pivoting and sharpening their assets through 00:24:41.569 --> 00:24:44.839 recent M &A. The M &A strategy post -Aderholm 00:24:44.839 --> 00:24:47.299 clearly indicates a pivot back to their strength. 00:24:47.480 --> 00:24:50.579 High value, rare disease portfolios and specialized 00:24:50.579 --> 00:24:54.400 technology. In July 2023, they executed a major 00:24:54.400 --> 00:24:56.960 deal. Acquiring Riata Pharmaceuticals. For nearly 00:24:56.960 --> 00:25:02.019 $6 .5 billion. And Riata had Omavox alone, SkyClarys, 00:25:02.079 --> 00:25:04.460 which we discussed for Friedreich's Ataxia. This 00:25:04.460 --> 00:25:06.559 acquisition wasn't about diversification, but 00:25:06.559 --> 00:25:08.420 consolidation, right? It was pure concentration. 00:25:08.599 --> 00:25:10.900 It was a clear signal to the market that despite 00:25:10.900 --> 00:25:13.799 the high profile... failure in Alzheimer's, Biogen 00:25:13.799 --> 00:25:15.880 was committed to rare, high -impact neurological 00:25:15.880 --> 00:25:18.259 disorders where they have proven market success 00:25:18.259 --> 00:25:20.779 and high pricing power. Like with Spinraza. Exactly. 00:25:21.059 --> 00:25:24.039 The $6 .5 billion price tag ensured they solidified 00:25:24.039 --> 00:25:25.859 their position in this niche segment. And the 00:25:25.859 --> 00:25:28.640 buying spree continued into 2024, still targeting 00:25:28.640 --> 00:25:31.200 specialized therapeutic areas. Absolutely. In 00:25:31.200 --> 00:25:35.059 May 2024, they acquired Human Immunology Biosciences, 00:25:35.059 --> 00:25:40.019 or H .I. Bio, for $1 .15 billion. This move was 00:25:40.019 --> 00:25:43.000 about reinforcing their pipeline with more monoclonal 00:25:43.000 --> 00:25:45.700 antibodies, the same kind of targeted technology 00:25:45.700 --> 00:25:48.799 that gave them RIT -UXAN and TASABRI. It all 00:25:48.799 --> 00:25:51.200 connect back. Yeah, iBuyBio's assets complement 00:25:51.200 --> 00:25:54.279 Biogen's existing immunology work, which is essential 00:25:54.279 --> 00:25:56.900 for treating conditions like MS. Finally, we 00:25:56.900 --> 00:25:59.099 see an acquisition focused purely on delivery 00:25:59.099 --> 00:26:01.599 technology, connecting directly back to their 00:26:01.599 --> 00:26:03.940 current successful rare disease treatments. The 00:26:03.940 --> 00:26:07.000 September -November 2025 acquisition of Alcyone 00:26:07.000 --> 00:26:10.789 Therapeutics for $85 million, while it's a smaller 00:26:10.789 --> 00:26:12.630 dollar amount, it was strategically crucial. 00:26:13.289 --> 00:26:15.710 Alcyone specializes in technology for spinal 00:26:15.710 --> 00:26:17.490 drug delivery. And why is this so important? 00:26:17.750 --> 00:26:20.029 Because treatments like Spinraza and many future 00:26:20.029 --> 00:26:22.950 CNS or central nervous system drugs must be delivered 00:26:22.950 --> 00:26:25.549 directly into the cerebrospinal fluid via spinal 00:26:25.549 --> 00:26:27.890 injection. Securing this proprietary delivery 00:26:27.890 --> 00:26:30.509 technology strengthens Biogen's long -term ability 00:26:30.509 --> 00:26:32.650 to administer their core neurological therapies 00:26:32.650 --> 00:26:35.049 safely and efficiently. It locks in a competitive 00:26:35.049 --> 00:26:38.210 edge. These billion -dollar strategic bets required 00:26:38.210 --> 00:26:42.529 internal consolidation. In 2023, they cut a significant 00:26:42.529 --> 00:26:45.309 portion of their workforce. The structural changes 00:26:45.309 --> 00:26:47.630 illustrate the brutal efficiency of the biotech 00:26:47.630 --> 00:26:52.130 sector. In July 2023, Biogen cut 1 ,000 jobs, 00:26:52.349 --> 00:26:54.950 representing 11 % of its workforce. That's a 00:26:54.950 --> 00:26:57.170 lot of people. It is. And while painful, it was 00:26:57.170 --> 00:26:59.789 framed as a necessary measure to streamline operations, 00:27:00.250 --> 00:27:03.369 cut legacy costs, and ensure capital was fully 00:27:03.369 --> 00:27:06.710 focused on the new high -value launches and integrating 00:27:06.710 --> 00:27:09.230 the newly acquired assets. At the same time, 00:27:09.230 --> 00:27:11.259 they... announced a massive $2 billion investment 00:27:11.259 --> 00:27:13.740 in expanding manufacturing facilities. In North 00:27:13.740 --> 00:27:16.220 Carolina's Research Triangle Park, yes. This 00:27:16.220 --> 00:27:18.900 contrast cost -cutting alongside huge capital 00:27:18.900 --> 00:27:21.299 investment shows a company retooling for efficiency 00:27:21.299 --> 00:27:23.779 and the long -term pipeline. Now we need to shift 00:27:23.779 --> 00:27:26.319 away from finance and strategy to two examples 00:27:26.319 --> 00:27:28.859 of operational turbulence that hit Biogen on 00:27:28.859 --> 00:27:30.980 a global scale. We have to start with a public 00:27:30.980 --> 00:27:33.000 health catastrophe linked to the company, the 00:27:33.000 --> 00:27:35.309 COVID -19 super spreader event. This is one of 00:27:35.309 --> 00:27:38.269 the most astonishing unintended corporate consequences 00:27:38.269 --> 00:27:40.609 in recent history. The event occurred at the 00:27:40.609 --> 00:27:43.589 very, very start of the pandemic. On March 5, 00:27:43.829 --> 00:27:46.789 2020, three attendees of a Biogen leadership 00:27:46.789 --> 00:27:49.710 conference held in Boston tested positive for 00:27:49.710 --> 00:27:52.670 COVID -19. And because it was a global gathering 00:27:52.670 --> 00:27:55.250 of leadership, the virus was instantly launched 00:27:55.250 --> 00:27:57.569 into international travel networks. It was an 00:27:57.569 --> 00:28:00.240 ideal vector for early global spread. By March 00:28:00.240 --> 00:28:02.440 9, Massachusetts health officials had announced 00:28:02.440 --> 00:28:05.660 30 new cases, all connected to that Biogen conference. 00:28:06.279 --> 00:28:09.680 But the true horrifying scope only became clear 00:28:09.680 --> 00:28:12.940 much later through genomic sequencing and epidemiological 00:28:12.940 --> 00:28:15.039 modeling. Wait, let me repeat these numbers because 00:28:15.039 --> 00:28:17.279 they are just staggering. The long term tracking 00:28:17.279 --> 00:28:19.579 of that single corporate meeting is hard to believe. 00:28:19.759 --> 00:28:22.740 It is truly shocking. Researchers painstakingly 00:28:22.740 --> 00:28:24.759 estimated that the virus lineage originating 00:28:24.759 --> 00:28:27.200 from that single Biogen conference would be linked 00:28:27.200 --> 00:28:29.779 to over 20 ,000 of Massachusetts. total cases. 00:28:29.880 --> 00:28:32.900 20 ,000. And internationally, the modeling estimated 00:28:32.900 --> 00:28:34.920 that the event was responsible for seating up 00:28:34.920 --> 00:28:39.519 to 300 ,000 cases worldwide. 300 ,000. Including 00:28:39.519 --> 00:28:43.839 approximately 1 .6 % of all U .S. COVID -19 cases 00:28:43.839 --> 00:28:47.299 in the early phases of the pandemic. 1 .6 % of 00:28:47.299 --> 00:28:49.640 all U .S. cases from one corporate gathering. 00:28:50.240 --> 00:28:53.180 That is an unbelievable, unintended public health 00:28:53.180 --> 00:28:57.019 impact that demonstrates just how quickly a globalized 00:28:57.019 --> 00:28:59.720 corporate structure can become an amplifier for 00:28:59.720 --> 00:29:01.839 infectious disease. It serves as a monumental 00:29:01.839 --> 00:29:04.519 historical footnote showing the profound responsibility, 00:29:04.859 --> 00:29:07.460 even unintended, that major global corporations 00:29:07.460 --> 00:29:10.099 carry beyond their core business. Moving from 00:29:10.099 --> 00:29:12.460 an unforeseen public health crisis to a deeply 00:29:12.460 --> 00:29:15.190 ethical and legal one. We need to discuss the 00:29:15.190 --> 00:29:18.289 $900 million lawsuit settlement related to their 00:29:18.289 --> 00:29:21.130 core MS drug business. This represents a significant 00:29:21.130 --> 00:29:23.890 ethical black mark for a company built on Nobel 00:29:23.890 --> 00:29:27.490 -winning science. In September 2022, Biogen agreed 00:29:27.490 --> 00:29:30.450 to a massive settlement paying $900 million to 00:29:30.450 --> 00:29:32.490 the U .S. federal government, various states, 00:29:32.650 --> 00:29:34.529 and a whistleblower who brought the original 00:29:34.529 --> 00:29:36.730 suit. What were the specific claims that led 00:29:36.730 --> 00:29:38.710 to this near -billion -dollar settlement? The 00:29:38.710 --> 00:29:41.430 settlement resolved claims that Biogen had engaged 00:29:41.430 --> 00:29:55.829 in illegal, unethical sales. Avonex, Tesabri, 00:29:55.950 --> 00:30:03.470 and Tecfidera. The big three. It's a violation 00:30:03.470 --> 00:30:06.069 of anti -kickback statutes because it introduces 00:30:06.069 --> 00:30:08.910 a commercial incentive, money, trips, expensive 00:30:08.910 --> 00:30:12.029 meals, speaking fees, into what should be a completely 00:30:12.029 --> 00:30:14.869 ab - objective medical decision. The doctors 00:30:14.869 --> 00:30:16.710 are essentially compensated to steer patients 00:30:16.710 --> 00:30:19.049 toward the Biogen product, regardless of whether 00:30:19.049 --> 00:30:21.470 a generic or a competing less expensive drug 00:30:21.470 --> 00:30:23.509 might have been medically equivalent. And that 00:30:23.509 --> 00:30:26.049 artificially inflates drug costs. Which are then 00:30:26.049 --> 00:30:28.150 borne by federal and state health care programs, 00:30:28.309 --> 00:30:31.470 leading to the massive civil penalty. The juxtaposition 00:30:31.470 --> 00:30:34.049 is just so stark. A company that provides these 00:30:34.049 --> 00:30:37.230 life -altering revolutionary therapies was simultaneously 00:30:37.230 --> 00:30:39.990 utilizing fundamentally corrupt practices to 00:30:39.990 --> 00:30:42.240 boost the sales of those very same treatments. 00:30:42.259 --> 00:30:44.740 Let's try to synthesize all of this. Stepping 00:30:44.740 --> 00:30:47.920 back, Biogen is a quintessential high -stakes 00:30:47.920 --> 00:30:50.420 biotech enterprise. It began with the highest 00:30:50.420 --> 00:30:53.500 possible scientific pedigree, a foundation forged 00:30:53.500 --> 00:30:56.420 by Nobel laureates, and leveraged that credibility 00:30:56.420 --> 00:30:59.579 to pioneer treatments like Spinraza, which fundamentally 00:30:59.579 --> 00:31:02.559 altered the prognosis for children with SMA. 00:31:02.720 --> 00:31:05.079 And they built an unassailable dominance in the 00:31:05.079 --> 00:31:08.079 massive MS market. despite the inherent risks 00:31:08.079 --> 00:31:11.480 like PML associated with Tysabri. But this scientific 00:31:11.480 --> 00:31:14.619 excellence is inextricably linked to immense 00:31:14.619 --> 00:31:17.859 operational volatility. We've seen the calculated 00:31:17.859 --> 00:31:20.579 risk of acquiring Tysabri, the shocking financial 00:31:20.579 --> 00:31:23.440 failure of Adihelm, the ethical fallout from 00:31:23.440 --> 00:31:26.160 the $900 million kickback settlement, and the 00:31:26.160 --> 00:31:28.599 completely unforeseen global impact of the COVID 00:31:28.599 --> 00:31:31.059 super spreader event. It's a story of maximum 00:31:31.059 --> 00:31:34.319 innovation meeting maximum turbulence. Financially, 00:31:34.400 --> 00:31:36.819 they remain a powerhouse, rapidly pivoting their 00:31:36.819 --> 00:31:39.339 investment after the Adihelm loss to reinforce 00:31:39.339 --> 00:31:41.660 their high -margin rare disease specialization, 00:31:41.740 --> 00:31:44.099 as we saw in the costly acquisitions of Rayada 00:31:44.099 --> 00:31:47.940 and H .I .Bio. focus remains laser sharp, solving 00:31:47.940 --> 00:31:49.720 the world's most difficult neurological problem. 00:31:49.839 --> 00:31:52.240 And that focus on the biggest prize, Alzheimer's, 00:31:52.299 --> 00:31:55.119 didn't actually vanish when Adalhom failed, did 00:31:55.119 --> 00:31:57.559 it? They learned lessons and immediately moved 00:31:57.559 --> 00:31:59.559 to the next generation of treatment. That is 00:31:59.559 --> 00:32:02.319 the critical final piece of context. Biogen's 00:32:02.319 --> 00:32:05.559 collaboration with ISI continued, yielding Olquimibia 00:32:05.559 --> 00:32:09.400 or Licanumab Irm. This drug, which also targets 00:32:09.400 --> 00:32:12.319 amyloid beta, received U .S. approval in 2023. 00:32:13.150 --> 00:32:15.029 And crucially, it was approved for patients in 00:32:15.029 --> 00:32:17.430 the mild cognitive impairment or mild dementia 00:32:17.430 --> 00:32:19.809 stages of Alzheimer's. And the data supporting 00:32:19.809 --> 00:32:22.670 its efficacy was far clearer than Aduhelm's, 00:32:22.769 --> 00:32:25.410 allowing it to navigate a much less controversial 00:32:25.410 --> 00:32:28.750 path to market. It confirms that Biogen is not 00:32:28.750 --> 00:32:30.569 stepping away from this challenging therapeutic 00:32:30.569 --> 00:32:32.730 area. Here's something to think about, given 00:32:32.730 --> 00:32:35.079 everything we've covered. The entire Idaho Helm 00:32:35.079 --> 00:32:37.220 saga, the enormous investment, the contradictory 00:32:37.220 --> 00:32:40.240 clinical trials, the FDA overgetting its advisory 00:32:40.240 --> 00:32:42.559 panel, and the ultimate commercial rejection. 00:32:42.900 --> 00:32:45.579 It provides a textbook case study. It really 00:32:45.579 --> 00:32:47.500 does. It raises an important question about how 00:32:47.500 --> 00:32:50.119 society weighs the urgency of finding a cure 00:32:50.119 --> 00:32:52.900 for a universally feared condition like Alzheimer's 00:32:52.900 --> 00:32:55.420 against the certainty and solidity of clinical 00:32:55.420 --> 00:32:58.519 data. The FDA's reliance on the accelerated approval 00:32:58.519 --> 00:33:01.759 pathway in this case forced a drug onto the market. 00:33:01.859 --> 00:33:04.039 That the market itself, through insurers and 00:33:04.039 --> 00:33:06.920 practitioners, eventually rejected due to insufficient 00:33:06.920 --> 00:33:09.720 verified clinical benefit and prohibitive cost. 00:33:10.160 --> 00:33:12.200 So what does that tell us about the future of 00:33:12.200 --> 00:33:14.799 drug development for catastrophic diseases? It 00:33:14.799 --> 00:33:17.180 suggests that while accelerated approval can 00:33:17.180 --> 00:33:20.119 offer hope quickly, if the subsequent conservatory 00:33:20.119 --> 00:33:23.240 data is weak, the entire regulatory and commercial 00:33:23.240 --> 00:33:26.549 system risks being destabilized. Creating enormous 00:33:26.549 --> 00:33:29.349 financial cost and undermining public trust in 00:33:29.349 --> 00:33:32.349 the name of speed. It forces us to ask, should 00:33:32.349 --> 00:33:34.529 the standard for such urgent conditions be high 00:33:34.529 --> 00:33:38.089 certainty data first or high speed access? Biogen 00:33:38.089 --> 00:33:40.430 lived through the most expensive possible answer 00:33:40.430 --> 00:33:42.670 to that question. A profound and challenging 00:33:42.670 --> 00:33:44.930 question for regulators, drug makers, and every 00:33:44.930 --> 00:33:47.329 patient hoping for a cure. Thank you for diving 00:33:47.329 --> 00:33:48.069 deep with us today.